NCT02280317View on ClinicalTrials.gov

Dose Finding Safety Study of VAL201 in Cancer Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

January 27, 2020

Study Completion Date

January 27, 2020

Conditions
Stage III Prostate CarcinomaStage IV Prostate Carcinoma
Interventions
DRUG

VAL201

VAL201-001 Sub-cutaneous injection.

All Listed Sponsors
lead

ValiRx Plc

INDUSTRY

NCT02280317 - Dose Finding Safety Study of VAL201 in Cancer Patients | Biotech Hunter | Biotech Hunter